Biomarin Pharmaceutical (LTS:0HNC) Long-Term Debt : $594 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Biomarin Pharmaceutical Long-Term Debt?

Biomarin Pharmaceutical's Long-Term Debt for the quarter that ended in Mar. 2024 was $594 Mil.

Biomarin Pharmaceutical's quarterly Long-Term Debt increased from Sep. 2023 ($593 Mil) to Dec. 2023 ($593 Mil) and increased from Dec. 2023 ($593 Mil) to Mar. 2024 ($594 Mil).

Biomarin Pharmaceutical's annual Long-Term Debt increased from Dec. 2021 ($1,079 Mil) to Dec. 2022 ($1,083 Mil) but then declined from Dec. 2022 ($1,083 Mil) to Dec. 2023 ($593 Mil).

Biomarin Pharmaceutical Long-Term Debt Historical Data

The historical data trend for Biomarin Pharmaceutical's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Long-Term Debt Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

486.24

1,075.15

1,079.08

1,083.02

593.10

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															1,084.01	1,084.99	592.59	593.10	593.61

Biomarin Pharmaceutical (LTS:0HNC) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Biomarin Pharmaceutical Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (LTS:0HNC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (LTS:0HNC) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (LTS:0HNC) Headlines

No Headlines